Busulfan

Generic Name
Busulfan
Brand Names
Busulfex, Myleran, Busulfan Fresenius Kabi
Drug Type
Small Molecule
Chemical Formula
C6H14O6S2
CAS Number
55-98-1
Unique Ingredient Identifier
G1LN9045DK
Background

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.

Associated Conditions
Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

First Posted Date
2014-05-06
Last Posted Date
2017-12-22
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
8
Registration Number
NCT02130869
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

First Posted Date
2014-05-02
Last Posted Date
2021-05-07
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
14
Registration Number
NCT02129582
Locations
🇺🇸

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

First Posted Date
2014-04-22
Last Posted Date
2021-11-26
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
35
Registration Number
NCT02120157
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Washington University in St. Louis, Saint Louis, Missouri, United States

🇨🇦

British Columbia Children's Hospital, Vancouver, British Columbia, Canada

and more 6 locations

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

First Posted Date
2014-04-15
Last Posted Date
2014-07-11
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT02114502

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

First Posted Date
2014-03-11
Last Posted Date
2022-01-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
70
Registration Number
NCT02083250
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

First Posted Date
2014-02-13
Last Posted Date
2024-06-04
Lead Sponsor
Diane George
Target Recruit Count
14
Registration Number
NCT02061800
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

First Posted Date
2014-02-07
Last Posted Date
2018-10-12
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
25
Registration Number
NCT02057770
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.

Phase 2
Recruiting
Conditions
Acute Lymphoblastic Leukemia
Interventions
Drug: Busulfan
First Posted Date
2014-01-28
Last Posted Date
2023-02-06
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
38
Registration Number
NCT02047578
Locations
🇰🇷

Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD

Phase 1
Recruiting
Conditions
Genetic Rare Disease
Interventions
Drug: Busulfan
First Posted Date
2014-01-13
Last Posted Date
2023-02-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
5
Registration Number
NCT02034630
Locations
🇰🇷

Seoul National University Hospital, Seoul, Daehangno, Jongno-gu, Korea, Republic of

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

First Posted Date
2013-12-11
Last Posted Date
2015-12-28
Lead Sponsor
University of Miami
Target Recruit Count
2
Registration Number
NCT02007863
Locations
🇺🇸

Jackson Memorial Hospital, Miami, Florida, United States

🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy